Peer-influenced content. Sources you trust. No registration required. This is HCN.
American Journal of Endocannabinoid Medicine (AJEM)
This longitudinal study offers valuable insights into the complex effects of medical cannabis on quality of life in anxiety patients. Physicians may find the nuanced findings on mental and physical well-being particularly relevant for treatment considerations.
Family Medicine/General Practice August 30th 2023
Medical Professionals Reference (MPR)
The recent PALISADE-2 trial has revealed promising results for fasedienol nasal spray in treating social anxiety disorder. Explore the significant findings and potential implications for future anxiety treatments.
Psychiatry August 15th 2023
Epoch Health
The relationship between anxiety and gut health opens up new avenues for understanding and treating anxiety diarrhea. By exploring dietary adjustments, probiotic supplements, herbal interventions, and complementary therapies, physicians may find comprehensive solutions for their patients dealing with these distressing symptoms.
Gastroenterology August 2nd 2023
Journal of Dental Research
Explore the resilience of Canadian dentists during the COVID-19 pandemic, as revealed by a year-long study that used salivary cortisol levels to measure stress and anxiety. Discover how they navigated the challenges and maintained their mental health amidst the crisis.
Dentistry July 17th 2023
Neurology Advisor
Age, a Critical Moderator in Anxiety/Depression and Cognitive Outcomes in MS In recent findings from the ACTRIMS Forum 2023, researchers underscored the crucial role of age in the relationship between mental health and cognitive outcomes in patients with multiple sclerosis (MS). Key Points: “Considering age is necessary when exploring the links between depression or anxiety and cognition in people with MS.” Researchers from the University of Toronto
Geriatrics June 13th 2023
The SSRI inhibitor was previously limited to adults. As physicians, we are continually seeking effective treatment options for our pediatric patients. The recent FDA approval of Lexapro for pediatric GAD treatment marks a significant advancement in this field.
Family Medicine/General Practice June 6th 2023